For both the Pfizer-BioNTech and Moderna mRNA vaccines ... This is the zone of subjective opinion. Some examples: Tattoos are cool. Dogs make better pets than cats. Shoes with brown leather ...

Pfizer’s transition from pandemic reliance to growth in oncology and rare diseases reflects a strategic pivot, supported by recent acquisitions, despite the challenge of rising debt ...

Board of Directors approves quarterly cash dividend of $0.42 per share NEW YORK, October 09, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $ ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pfizer has earned a nod from the U.S. regulator for another of its products in the indication. On Friday, the FDA signed ...

Pfizer stock (NYSE: PFE) is trading at about $30 per share, not far from the lows seen in recent years. Could the stock rise by over 2x in value over the next few years? Does this sound a bit ...

Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 billion acquisition the New York pharma made two years ago. Pfizer will ...

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.

Beata Zawrzel / NurPhoto via Getty Images Pfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of safety concerns. The drug maker said the benefits of Oxbryta no ...

On Wednesday, Pfizer Inc. (NYSE:PFE) said the company is voluntarily withdrawing all lots of Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where ...

LONDON, Sept 25 (Reuters) - Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the ...

Pfizer (NYSE:PFE) has voluntarily withdrawn all lots of its sickle cell disease drug Oxbryta, also known as voxelotor, over safety concerns. The pharmaceutical giant said Oxbryta will be withdrawn ...

Sept 26 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks ...